Eterna Therapeutics Inc.

AI Score

0

Unlock

0.35
-0.01 (-3.21%)
At close: Feb 04, 2025, 3:59 PM
0.35
-1.43%
After-hours Feb 04, 2025, 07:59 PM EST
undefined%
Bid 0.35
Market Cap 18.01M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -8.31
PE Ratio (ttm) -0.04
Forward PE n/a
Analyst n/a
Ask 0.37
Volume 454,366
Avg. Volume (20D) 11,284,478
Open 0.36
Previous Close 0.36
Day's Range 0.34 - 0.37
52-Week Range 0.22 - 2.63
Beta undefined

About ERNA

Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics,...

Industry Biotechnology
Sector Healthcare
IPO Date Aug 29, 1991
Employees 8
Stock Exchange NASDAQ
Ticker Symbol ERNA
3 weeks ago
+48.22%
Eterna Therapeutics shares are trading higher afte... Unlock content with Pro Subscription